|
|
|
| Research progress of Pemetrexed nanoformulation |
| LING Jianxin1,2,3 NING Qian2 TANG Shengsong1,2 |
1.Institute of Pharmacy and Pharmacology, University of South China, Hu′nan Province, Hengyang 421001, China;
2.Hu′nan Province Key Laboratory for Antibody-based Drug and Intelligent Delivery System, Hu′nan University of Medicine, Hu′nan Province, Huaihua 418000, China; 3.Department of Pharmacy, the First Affiliated Hospital of Hu′nan University of Medicine, Hu′nan Province, Huaihua 418000, China |
|
|
|
Abstract Pemetrexed (PEM) is a new generation of anti-tumor drug that blocks multiple targets of folate metabolism pathway, and it is more effective than other traditional anti-folate drugs. However, due to the lack of tumor specificity and dose-dependent toxicity, its clinical application is limited. Nanocarriers have attracted wide attention because of their unique advantages in reducing toxicity and improving therapeutic effect. In recent years, studies on PEM nanoparticles, including liposomes, nanoparticles, micelles, nanoemulsions and hydrogels, have made some progress in improving the solubility of PEM, prolonging the circulation time in vivo, improving targeting, reducing adverse reactions and enhancing anti-tumor activity, and different drug delivery methods have been developed. This paper reviews the research progress of PEM nanopreparation, and provides the theoretical basis for the development and application of new PEM nanopreparation.
|
|
|
|
|
|
[1] Adjei AA. Pharmacology and Mechanism of Action of Pemetrexed [J]. Clin Lung Cancer，2004，5（supp-S2）：S51-S55.
[2] Curtin NJ，Hughes AN. Pemetrexed disodium，a novel antifolate with multiple targets [J]. Lancet Oncol，2001，2（5）：298-306.
[3] Chattopadhyay S，Moran RG，Goldman ID. Pemetrexed：biochemical and cellular pharmacology，mechanisms，and clinical applications [J]. Mol Cancer Ther，2007，6（2）：404-417.
[4] Dong X，Mumper RJ. Nanomedicinal strategies to treat multidrug resistant tumors：current progress [J]. Nanomedicine （Lond），2010，5（4）：597-615.
[5] Gao J，Feng SS，Guo Y. Nanomedicine against multidrug resistance in cancer treatment [J]. Nanomedicine （Lond），2012，7（4）：465-468.
[6] Akbarzadeh A，Rezaei-Sadabady R，Davaran S，et al. Liposome：classification， preparation，and applications [J]. Na-noscale Res Lett，2013，8（1）：102-111.
[7] Bai F，Yin Y，Chen T，et al. Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer [J]. Int J Nano-medicine，2018，13：1327-1339.
[8] Essam Eldin N，Elnahas HM，Mahdy MA. Liposomal pemetrexed：formulation，characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma [J]. Biol Pharm Bull，2015，38（3）：461-469.
[9] Eldin NE，Abu Lila AS，Kawazoe K，et al. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model [J]. Eur J Pharm Sci，2016，81：60-66.
[10] Ando H，Kobayashi S，Abu Lila AS，et al. Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed [J]. J Control Release，2015，220（Pt A）：29-36.
[11] Vandana M. Reduced folate carrier independent internalization of PEGylated pemetrexed：a potential nanomedicinal approach for breast cancer therapy [J]. Mol Pharm，2012，9（10）：2828-2843.
[12] Yang W，Yang L，Xia Y，et al. Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo [J]. Acta Biomater，2018，70：177-185.
[13] Gialeli C，Theocharis AD. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting [J]. FEBS J，2011，278（1）：16-27.
[14] Lu N，Liu Q，Li R，et al. Superior antimetastatic effect of pemetrexed-loaded gelatinase-responsive nanoparticles in a mouse metastasis model [J]. Anticancer Drugs，2012， 23（10）：1078-1088.
[15] Stolarczyk EU，Stolarczyk K，?覵aszcz M，et al. Pemetrexed conjugated with gold nanoparticles-Synthesis，characterization and a study of noncovalent interactions [J]. Eur J Pharm Sci，2017，109：13-20.
[16] Mohapatra S，Rout SR，Narayan R. Multifunctional mesoporous hollow silica nanocapsules for targeted co-delivery of cisplatin-pemetrexed and MR imaging [J]. Dalton Trans，2014，43（42）：15841-15850.
[17] Zhao MX，Zhu BJ，Yao WJ，et al. Therapeutic effect of quantum dots for cancer treatment [J]. RSC Adv，2016，6（114）：113791-113795.
[18] Zayed DG，Ebrahim SM，Helmy MW，et al. Combining hydrophilic chemotherapy and hydrophobic phytotherapy via tumor-targeted albumin-QDs nano-hybrids：covalent coupling and phospholipid complexation approaches [J]. J Nanobiotechnology，2019，17（1）：7-26.
[19] Krishnamurthy S，Vaiyapuri R，Zhang L. Lipid-coated polymeric nanoparticles for cancer drug delivery [J]. Biomater Sci，2015，3（7）：923-936.
[20] Kü?觭üktürkmen B，Devrim B，Saka OM，et al. Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid-polymer hybrid nanoparticles and effects on glioblastoma cells [J]. Drug Dev Ind Pharm，2017，43（1）：12-21.
[21] Kü?觭üktürkmen B. Development and characterization of cationic solid lipid nanoparticles for co-delivery of pemetrexed and miR-21 antisense oligonucleotide to glioblastoma cells [J]. Drug Dev Ind Pharm，2018，44（2）：306-315.
[22] Lock LL，Li Y，Mao X，et al. One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents [J]. ACS Nano，2017，11（1）：797-805.
[23] Pangeni R，Choi JU，Panthi VK，et al. Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations：preparation，characterization，and in vivo oral bioavailability and anticancer effect [J]. Int J Nanomedicine，2018，13：3329-3351.
[24] Pangeni R，Panthi VK，Yoon IS，et al. Preparation，Characterization，and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin [J]. Pharmaceutics，2018，10（3）.pii：E158.
[25] Service RF. Nanotechnology．Nanoparticle Trojan horses gallop from the lab into the clinic [J]. Science，2010，330（6002）：314-315. |
|
|
|
